A detailed history of Bank Of America Corp transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 261,031 shares of AVTE stock, worth $694,342. This represents 0.0% of its overall portfolio holdings.

Number of Shares
261,031
Previous 19,160 1262.37%
Holding current value
$694,342
Previous $31,000 1658.06%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.61 - $2.09 $389,412 - $505,510
241,871 Added 1262.37%
261,031 $545,000
Q2 2024

Aug 14, 2024

BUY
$1.41 - $30.75 $14,442 - $314,972
10,243 Added 114.87%
19,160 $31,000
Q1 2024

May 15, 2024

SELL
$17.68 - $29.57 $243,648 - $407,504
-13,781 Reduced 60.71%
8,917 $263,000
Q4 2023

Feb 14, 2024

BUY
$9.58 - $24.25 $157,131 - $397,748
16,402 Added 260.51%
22,698 $513,000
Q2 2023

Aug 14, 2023

SELL
$15.63 - $22.01 $109,503 - $154,202
-7,006 Reduced 52.67%
6,296 $107,000
Q1 2023

May 12, 2023

BUY
$19.17 - $27.7 $110,150 - $159,164
5,746 Added 76.05%
13,302 $268,000
Q4 2022

Feb 10, 2023

SELL
$15.92 - $30.52 $82,322 - $157,818
-5,171 Reduced 40.63%
7,556 $221,000
Q3 2022

Nov 14, 2022

BUY
$14.77 - $25.79 $157,979 - $275,849
10,696 Added 526.64%
12,727 $211,000
Q2 2022

Aug 12, 2022

SELL
$10.8 - $16.91 $22,377 - $35,037
-2,072 Reduced 50.5%
2,031 $31,000
Q1 2022

May 16, 2022

SELL
$8.25 - $18.33 $44,649 - $99,201
-5,412 Reduced 56.88%
4,103 $75,000
Q4 2021

Feb 08, 2022

BUY
$9.14 - $21.54 $78,914 - $185,976
8,634 Added 980.02%
9,515 $112,000
Q3 2021

Nov 15, 2021

BUY
$11.76 - $22.49 $10,360 - $19,813
881 New
881 $18,000

Others Institutions Holding AVTE

About Aerovate Therapeutics, Inc.


  • Ticker AVTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,448,100
  • Market Cap $65M
  • Description
  • Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...
More about AVTE
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.